Indivior PLC: The Nomination Committee Has Started a Search for a Successor
Indivior PLC: Hetherington Has Been a Board Member for Five Years
Indivior PLC Chair Graham Hetherington To Retire At the End of 2024
Indivior PLC Announces Total Voting Rights
Express News | Indivior PLC : Craig-Hallum Cuts Target Price to $20 From $24
Top 3 Health Care Stocks That May Explode This Month
Northland Securities Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $25
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $22
BlackRock Reduces Stake in Indivior Below 5%
Stifel Initiates Indivior(INDV.US) With Buy Rating, Announces Target Price $28.48
Maintaining Buy Rating: Indivior's Growth Prospects and Undervaluation Despite Near-Term Challenges
Indivior PLC Advances Share Repurchase Program
Smith & Wesson Brands Reports Downbeat Results, Joins Planet Labs PBC, Broadcom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Deutsche Bank Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $20.34
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
Indivior to Forgo Option to License Aelis Farma's Cannabis Use Disorder Drug
Indivior Faces Setback in Cannabis Disorder Treatment Trial
Aelis Farma Announces the Results of Its Clinical Phase 2B Study With AEF0117, Among Participants With Cannabis Use Disorder (CUD)
Indivior Announces Current Share Capital Structure